MacroGenics, Inc.

Dr. Nordstrom’s work in the lab helps research teams learn as much as possible about cancer drugs, like how they work and important safety information, before they are provided to patients in clinical trials.

New #JITC review: Role of Fcγ receptors in HER2-targeted breast cancer therapy bit.ly/3n1m6Uj @a_musolino @hoperugo @Farnaldez3 @DrWGradishar

MacroGenics provides update on corporate progress and Q3 2021 financial results bit.ly/3bQM07j

Today is Metastatic Breast Cancer Awareness Day. Visit MBCAlliance.org to learn about the disease that affects thousands of people both today and every day. #MetastaticBreastCancerAwarenessDay

MacroGenics honors the survivors and those we’ve lost during #BreastCancerAwareness month. We continue our work to increase research around this all-too-common disease.

Excited to announce preliminary clinical results from Ph 1 Cohort Expansion of ongoing MGC018 study at #ESMO21 bit.ly/3ElNMKt

We are pleased to share our clinical results from Cohort A Pt 1 of Ph 2/3 MAHOGANY study of margetuximab in combination with retifanlimab in gastroesophageal adenocarcinoma at #ESMO21 bit.ly/2XyBXjB

MacroGenics Announces Presentations at ESMO 2021 Virtual Annual Congress #ESMO21 $MGNX bit.ly/3A6UhOP

MacroGenics Announces Final Overall Survival Results from SOPHIA Study of MARGENZA™ bit.ly/3tpAnvJ

On Wednesday, Zai Lab Ltd. entered a deal with @MacroGenics Inc. covering up to four CD3- or CD47-based bispecifics. The expanded collaboration will give the Shanghai-based biotech broader Asia and worldwide rights to multiple cancer programs bit.ly/3wxgQdC $ZLAB $MGNX

Pleased to Announce Preliminary Clinical Results from Phase 1 Study of MGC018 to be Presented at ASCO Annual Meeting #ASCO21 bit.ly/3bHKwMO

We are happy to announce that @MacroGenics has decided to partner with Genedata to advance their translational and clinical research programs. Learn more on: bit.ly/GDMacroGenics #GenedataProfiler #ClinicalResearch #PrecisionMedicine #Immunotherapy

We are excited to announce that Federica O’Brien has joined our Board of Directors. $MGNX Read our announcement here: bit.ly/3jJVUe3

SOPHIA trial results have been published in @JAMAOnc; these data describe a new treatment option for adults with metastatic HER2+ breast cancer. Read more here: ir.macrogenics.com/news-releases/…

Living with metastatic HER2-positive breast cancer and not sure where to turn? Check out the @mbcalliance for information and support services. You can learn from others, share experiences and more: mbcalliance.org

Scientific advances are bringing women with metastatic HER2-positive #breastcancer the benefits of cutting-edge medical innovations - but there remains unmet need, as patients’ disease progresses. #MBC

This marks the first FDA approval for MacroGenics – thank you to the patients, physicians, nurses and staff involved in the clinical trial and to our employees who’ve worked to bring important therapies to patients in need.

Today, we announced the FDA approval of a treatment option for patients living with metastatic HER2-positive #breastcancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease #MBC. Read more: bit.ly/2WlAB7t

#metastaticbreastcancerawareness mbcalliance.org/support